Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.60 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569794 | 0.93 | EGFR (0.60) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL5563923 | 0.92 | EGFR (0.59) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL5567847 | 0.92 | EGFR (0.62) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL5568024 | 0.85 | EGFR (0.59) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL5568824 | 0.85 | EGFR (0.65) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL9973619 | 0.84 | ERBB2 (0.73) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL5569168 | 0.84 | EGFR (0.64) | EGFRERBB2LCKKCNH2AURKA | |
| SCHEMBL5568062 | 0.83 | EGFR (0.61) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL5564685 | 0.83 | EGFR (0.67) | EGFRERBB2LCKKCNH2AURKA | |
| SCHEMBL5567987 | 0.83 | EGFR (0.63) | EGFRERBB2LCKKCNH2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1664028-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026151-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ABL1, ERBB2, LCK | EGFR 15/4885ERBB2 2/4885LCK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.